Revaprazan
- Generic Name
- Revaprazan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23FN4
- CAS Number
- 199463-33-7
- Unique Ingredient Identifier
- 5P184180P5
- Background
Revaprazan is under investigation in clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(nerd)).
- Indication
用于治疗十二指肠溃疡和胃炎。该药治疗胃溃疡的适应症已完成临床Ⅲ期研究,治疗胃食管反流症、功能性消化不良以及幽门螺杆菌的适应症也已进入临床Ⅱ期研究。而在英国，该药由葛兰素史克负责开发，其治疗胃食管反流病适应症的研究已进入Ⅰ期临床阶段。目前国内尚未上市。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT03378284
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath